Hutchmed confirms new drug application for fruquintinib in Japan - Sharecast.com
HMP Receives Approval For Elunate | Contract Pharma
China Approves Home-Grown Colon Cancer Drug - Asian Scientist Magazine
Chi-Med announces first commercial launch of fruquintinib capsules (Elunate)
StudyPages - Clinical trial with Fruquintinib in patients with Metastatic Colorectal Cancer who has not responded to previous treatment
Fruquintinib Plus Toripalimab Is an Effective Third-Line Treatment of Advanced Colorectal Cancer | Docwire News
Fruquintinib - Wikipedia
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study - The Lancet
Fruquintinib API Manufacturer and Supplier | CAS 1194506-26-7 - Dr. Reddy's
Chi-Med goes global
Efficacy of fruquintinib confirmed in refractory metastatic colorectal cancer - Medical Update Online
Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer | Business Wire
Untitled
WuXi AppTec Partner Hutchison MediPharma Receives Approval of Fruquintinib Capsules in China | World Pharma Today
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial | SpringerLink
Suzhou Industrial Park
Overseas Marketing of Fruquintinib Accelerated as It Receives the FDA's Fast Track Designation
Hutchison MediPharma receives approval of Fruquintinib capsules in China
China approves first "Made in China" cancer drug
Fruquintinib significantly extends survival in refractory metastatic colorectal cancer
